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Abstract
Background: Chronic pain in older people is highly prevalent, often underestimated, and associated with adverse
outcomes. Most available analgesic drugs are often either ineffective or not tolerated, with many side effects.
Palmitoylethanolamide (PEA) is an endogenous widely distributed N-acylethanolamina involved in
neuroinflammation and pain-generating processes. Formulations containing ultra-micronized
palmitoylethanolamide (um-PEA) are available but their effectiveness on chronic pain in highly heterogeneous
geriatric patients is not clear and probably not generalizable. We planned to adopt the N-of-1 trial approach to test
the effectiveness of um-PEA objectively at the individual level in our older outpatients.
Methods/Design: Persons 65 years or older referring to the Geriatric Unit of the Fondazione IRCCS Ca’ Granda
Ospedale Maggiore Policlinico of Milan complaining of noncancer chronic pain of any origin will be eligible. Each trial
will be a placebo-controlled randomized crossover trial including two um-PEA (600 mg twice a day) and placebo
treatment pairs. The um-PEA or placebo 3-week periods will be separated by 2-week washout intervals to overcome
possible carryover effects. Pain intensity, need of on-demand analgesic medications, and impact on daily activities will
be evaluated. Cognitively impaired patients will be eligible as long as an expression of pain can be recognized and its
frequency assessed by a caregiver. Trial results will be discussed with the patient or caregiver and the treating physician
to decide whether to continue the treatment. The impact of the N-of-1 approach on the physician’s management plan
and confidence will be assessed. We will secondarily meta-analyze the performed N-of-1 trials to obtain an estimate of
the average effect of um-PEA compared with placebo using a frequentist and Bayesian approach.
Discussion: While pursuing an ultimate clinical objective, i.e. to empirically and objectively decide the best treatment
choice for an individual older patient with chronic pain, these series of geriatric N-of-1 trials on PEA will bring the
principles of evidence-based medicine into the care of patients not usually represented in conventional randomized
controlled trials, and realize a patient-centered outcome approach necessary to improve appropriate prescribing in
elderly patients with multimorbidity and polypharmacy.
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Background
Pain prevalence increases with age. In particular, the
prevalence of chronic or persistent pain among older
people ranges from 45 % to 80 % [1]. Persistent pain is a
frequent reason for physician office visits among older
persons [2], with women being more likely to report per-
sistent pain than men [3]. Among older adults, the most
frequent noncancer pain complaints are osteoarthritic back
pain, especially in the low back or neck (around 65 %),
musculoskeletal pain (around 40 %), peripheral neuro-
pathic pain (typically due to diabetes or post-herpetic neur-
algia, 35 %) and chronic joint pain (15 %–25 %) [4–6]. In
fact, persistent pain may or may not be associated with a
well-defined disease process [7].
Persistent pain and its inadequate treatment are asso-
ciated with adverse outcomes in older people: functional
impairment, falls, slow rehabilitation, mood changes,
and sleep and appetite disturbances, resulting in a higher
consumption of healthcare resources [8].
Achieving pain control in geriatric patients is compli-
cated by many issues. First, older people may underreport
pain, and in this population persistent pain has often com-
plex and multifactorial manifestations. Self-reporting is
deemed to be the gold standard in pain assessment but
older people might find difficult to complete self-reported
questionnaires of pain and functional status, developed
and validated in younger patients [7, 9]. Pain evaluation is
particularly cumbersome in older patients affected by
dementia, who can express pain through unusual verbal
and non-verbal modalities. Facial expression, verbalizations,
non-verbal sounds, body movements, variations in interper-
sonal relationships, and mental status changes might be
pain manifestations, and should be taken into account in
pain evaluation even if extremely non-specific [1].
Second, the somatosensory system changes with aging
[10], through the alteration or loss of myelinated and
unmyelinated nerve fibres [11], an impairment in the en-
dogenous opioid and non-opioid inhibitory systems of pain
modulation [12], and a modified neuroplasticity [13]. All
these changes lead to a reduced pain threshold, dysfunc-
tional pain signaling, hyperalgesia, and central sensitization.
Third, pharmacological management of chronic pain is
particularly challenging in the elderly. Owing to age-
related body changes affecting drug pharmacokinetics,
and because of multimorbidity and polypharmacy, older
patients are generally more likely to experience drug-
related adverse effects [7]. In particular, safety concerns
can arise with most of the available analgesic drug classes.
Given a better safety profile than traditional nonsteroidal
anti-inflammatory drugs, acetaminophen is usually indi-
cated as first line therapy for pain [7]. However, concerns
about its efficacy on low back pain and osteoarthritis of
the hip or knee, and about its actual safety, especially at
the upper end of standard analgesic doses, have been
raised by two recent systematic reviews of, respectively,
randomized placebo-controlled trials [14] and observa-
tional studies [15]. Nonsteroidal anti-inflammatory drugs
are more effective in the treatment of chronic inflamma-
tory pain, but are burdened with many side effects, such
as gastrointestinal bleeding, renal injury, and cardiovas-
cular toxicity, which increase in frequency and severity
with age [16, 17]. These safety issues are only partially
mitigated with cyclooxygenase-2 selective inhibitors
[18, 19]. Although their potential efficacy on persistent
noncancer pain has been proved in some controlled tri-
als, the adverse effects associated with opioids represent
a barrier to their adoption and a frequent reason of
drug discontinuation [20, 21]. In addition to other usual
adverse effects, such as constipation and nausea, a
negative impact on vigilance and cognitive performance
is common in older persons. Newly prescribed opioid
treatment has been associated with a higher risk of falls
[22], so that the 2015 update of Beers criteria on poten-
tially inappropriate medication use in older adults included
it among the considerations on disease and syndrome in-
teractions [23]. Although tolerance to central respiratory
depression develops quickly, rapid dose increase, drug–
drug interaction with other central nervous system depres-
sants, and drug accumulation or accidental overdose are
potential determinants of respiratory failure onset during
opioid treatment [24].
So called adjuvant (or pain-modulating) drugs, co-
administered with other analgesics, have been found to be
effective in attenuating pain perception, particularly in the
treatment of neuropathic pain [7]. They include antide-
pressants, anticonvulsants (e.g. pregabalin and gabapentin)
and other medications that alter neural membrane poten-
tials, ion channels, cell surface receptor sites, synaptic
neurotransmitter levels, and other neuronal processes in-
volved in pain signal processing. To minimize their poten-
tial adverse effects, these central nervous system drugs
must be carefully titrated and monitored frequently [7].
All pain-modulating therapies target neurons, the prin-
cipal component of the pain unit. However, a growing
body of evidence suggests that immune cells, in particular
mast cells and microglia, play a substantial role in the
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somatosensory system, being the primary interlocutors for
pain neurons, both in the periphery and at the spinal and
supraspinal levels [25]. Immune cells are located in prox-
imity to sensory nerve endings and vasculature. After an
injury or in the presence of an inflammatory stimulus, im-
mune cells release mediators, such as bradykinin, prosta-
glandins, and histamine, stimulating nociceptors and
playing an important role in the induction, amplification,
and maintenance of chronic pain [26]. Physiological acti-
vation of microglia generally leads to resolution of neuro-
inflammation and restoration of tissue homeostasis. With
aging, both microglia and mast cells increase their reactiv-
ity with a more intense response to a stimulus and a more
robust production of pro-inflammatory cytokines lasting
for an extended period [27, 28]. All these findings support
the hypothesis that non-neuronal cells might be important
therapeutic targets for the treatment of chronic pain, espe-
cially in older persons.
Palmitoylethanolamide (PEA) is an endogenous N-acy-
lethanolamina widely distributed in different tissues [29].
It is synthesized on demand and its levels vary after
stress or injuries, like those associated with pain [30]. In
murine models of chronic inflammation and chronic or
neuropathic pain, PEA seems to be able to reduce the
recruitment and activation of mast cells, the production
of pro-inflammatory mediators, and endoneural edema,
thus reducing both pain and inflammation while preserving
peripheral nerve morphology [31, 32]. Micronized or ultra-
micronized PEA (m- and um-PEA) is available in Italy as
an active molecule in several products classified as ‘Food
for Special Medical Purposes’ (European Commission
Directive 1999/21/EC), indicated for use ‘under medical
supervision’ to treat conditions whose pathogenesis in-
volves neuroinflammation. Evidence on the efficacy and
safety of PEA in the treatment of chronic or neuropathic
pain, alone or as add-on therapy, published as full articles
or conference abstracts, in peer-reviewed or non-peer-
reviewed journals, is currently based mostly on observa-
tional studies and case series, and on a few double-blind
or open label randomized controlled trials [33–37]. Re-
cently, in a meta-analysis of published and unpublished
data, Paladini et al. [38] confirmed the efficacy of PEA on
pain intensity independently of sex, age, and type of pain,
even if with a smaller effect in people older than 65 years.
Serious product-related adverse events were not reported
in any of the included studies.
The mechanism of action and the safety profile make PEA
an appealing choice for pain relief in older people. However,
the evidence base for its efficacy to treat chronic pain in the
elderly is not fully convincing. In addition, formulations con-
taining um-PEA, like Normast®, are available in Italy only
out-of-pocket and a treatment cycle at the doses recom-
mended by the product information sheet would cost the
patient about € 60. Given that the required treatment for
persistent pain would probably be longer, the cost should be
balanced by the actual effectiveness. These reasons repre-
sented the rationale to adopt a randomized N-of-1 trial as a
more objective and personalized prescribing approach, com-
pared with the conventional trial (i.e. ‘prescribe and see’) [39].
In general,N-of-1 trials are within-patient randomized multi-
period crossover trials to compare, in a double-blind fashion,
therapeutic strategies (e.g. an active drug versus no treat-
ments, or two different active therapies), with time periods as
randomization units and the patient as control for herself or
himself. This study design can be theoretically used to test
new drugs along their way to marketing authorization. In our
case, we will adopt this approach to determine the best thera-
peutic choice for a certain patient in clinical practice, object-
ively and empirically, with randomization and blindness as
instruments to overcome those factors (e.g. natural history of
the disease, ‘placebo effect’, expectations) that might bias con-
ventional trials of therapies [39–41]. In particular, the series of
N-of-1 trials on PEA for chronic pain in older patients will be
part of the activity of the Geriatric N-of-1 Service, an experi-
mental project that we have implemented, with the approval
of the local ethical committee, following the pioneering ex-
perience of Guyatt and colleagues [42] but in the specific con-
text of geriatric medicine, which suffers most from the limits
of parallel group randomized controlled trials, the current par-
adigms of evidence-basedmedicine [43].
Methods/Design
This study protocol has been realized according to the
CONSORT extension for reporting N-of-1 trials (CENT)
2015 [44] and the SPIRIT statements. The SPIRIT and
CENT checklists for our paper are provided as
Additional files 1 and 2, respectively.
Study objectives
The primary (clinical) objective of our study is to apply
the N-of-1 trial approach to test the effectiveness of um-
PEA 600 mg (Normast®) twice a day for chronic pain in
a certain patient referring to our geriatric unit in whom
the treatment might be indicated, and to assist decisions
on long-term treatment of that patient.
As a secondary (research) objective, we aim to obtain
an overall estimate of the effectiveness of um-PEA
600 mg twice a day compared with placebo and evaluate
the possible determinants of between-trial heterogeneity,
through a meta-analysis of the N-of-1 trials performed
for clinical purposes. Contextually, a classical frequentist
meta-analytical approach will be compared with a Bayes-
ian approach, and the potentialities of a Bayesian-based
cumulative study design explored.
Study design
Each trial will be a blinded placebo-controlled randomized
trial. Each trial’s duration will be 18 weeks, comprising
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two um-PEA and placebo treatment pairs assigned in a
random order according to a pairwise randomization
scheme. Thus, the sequence of each pair can be either
um-PEA/placebo or placebo/um-PEA. Each treatment
period will last 3 weeks. The treatment periods of each
pair and the two pairs will be separated by 2-week wash-
out intervals to minimize carryover effects. A run-in
period will not be routinely performed, but will be consid-
ered when deemed appropriate (for example, in case of
history of allergies to drugs or drug excipients). Figure 1
summarizes the schedule for the intervention and wash-
out periods.
This study design was conceived taking into account
the available information on the product pharmaco-
logical characteristics, balanced with the need for a trial
with an acceptable duration from the practical view-
point. The onset time of PEA is not easily predictable
from its pharmacokinetics or pharmacodynamics. Ac-
cording to the available literature, most people notice
the effects within 1 week, but sometimes 6–8 weeks are
required, especially for chronic pain syndromes. Regarding
a possible carryover effect, no sufficient data are currently
available, either from basic or clinical research studies, to
make a definitive statement. However, given the type of
mechanism of action, a possible residual effect might be
expected. Concerning the dose, in the heterogeneous
literature on the use of the product for pain control, differ-
ent doses have been tested, from 300 mg a day to
2400 mg a day, either once or split into three doses per
day. The product information sheet for Normast® 600 mg
suggests ‘1–2 tablets a day for 20–30 days’.
Eligibility criteria for participants
Older patients complaining of chronic pain of likely
osteoarticular or neuropathic origin will be eligible for
the study. Detailed inclusion criteria are:
! Patient age ≥ 65 years.
! Pain is localized at the back (any level) or at the
joints or at the limbs.
! The pain is chronic, i.e. it has been present for at
least 6 months, even if with fluctuations.
! The pain is attributable to one or more of the following
conditions: osteoarthritis or osteoarthrosis; spondylosis;
radiculopathy; diabetic peripheral neuropathy;
post-herpetic neuralgia; chronic idiopathic axonal
polyneuropathy; fibromyalgia; or pain of uncertain
origin or idiopathic, as long as it has had and it is
expected to have a chronic nature, even if with
spontaneous fluctuations.
Fig. 1 SPIRIT Study diagram. Wn: week number, D: daily W: weekly. The study duration is 18 weeks. After the baseline assessment at time 0,
patients will have two pairs of active drug (3 weeks) and placebo (3 weeks) exposures. Randomly assigned treatment pairs will comprise two
treatment periods (active therapy or placebo) separated by a 2-week washout period. Treatment pairs will also be separated by washout periods
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! The treating physician deems PEA to be a possible
treatment option for the patient, either alone or as
an add-on medication on top of other analgesic
drugs.
Dealing with geriatric patients, and willing to offer the
opportunity of a treatment option with an objective and
empirical evaluation regardless of patient cognitive in-
tegrity, we will distinguish two cases:
! Case 1 (self-assessment): The patient is able to give
an informed consent and to express the
characteristics of the pain-like intensity and impact
on function over a quantitative scale; the patient
might be able to self-compile questionnaires, or to
reliably answer questions administered by a
caregiver.
! Case 2 (caregiver-based-assessment): The patient
has a certain degree of cognitive decline that hinders
the direct involvement of the patient in the consent
process or in the outcome self-assessment, but an
all-day caregiver willing to collaborate and consent
to the trial is present. In this case, the pain has to be
clearly expressed by the patient in a modality that
can be assessed in its frequency and impact on func-
tion by someone other than the patient.
N-of-1 trials on case 1 patients will be candidates for
the secondary objective of our study. The opportunity to
meta-analyze case 2 trials will be judged according to
the number and heterogeneity of the assessment instru-
ments and modalities of completed trials.
Patients with cancer-related pain and patients with a
clear ischemic pathogenesis for pain (e.g. intermittent
claudication or critical limb ischemia) will be excluded.
There will be no exclusion criteria concerning the co-
morbidities the patient might have. Patients can take
other medications or undergo non-pharmacological
therapies (e.g. physical therapies) for chronic pain con-
trol as long as they are not newly commenced; generally,
no therapy modification that can affect pain must have
been made soon before or concomitantly with the en-
rollment in the N-of-1 trial.
Setting and recruitment
The study will be conducted at the Geriatric Unit of the
Fondazione IRCCS Ca’ Granda – Ospedale Maggiore
Policlinico in Milan, Italy, which is an academic tertiary
hospital unit that serves inpatient and outpatient referrals.
Patients will be mainly recruited from the geriatric
outpatient clinic. Referrals might also be generated in
the inpatient clinic but, to be enrolled in the study, pa-
tients need to have recovered from any acute illness.
Interventions
One tablet containing either Normast® 600 mg or pla-
cebo will be administered orally twice daily during the
treatment periods. No study drug will be administered
during the washout period.
The patient will be allowed to take on-demand pain-
killers during the entire trial duration. At the baseline
visit, the patient will be recommended according to our
usual geriatric practice, i.e. to take acetaminophen at a
maximum dose of 2 g daily if not contraindicated or in
case of drug allergy or intolerance; if acetaminophen is
insufficient, to combine or replace it with codeine or
tramadol; to use ibuprofen when pain is not eventually
controlled, trying to avoid, in general, nonsteroidal anti-
inflammatory drugs. The patient will be given instruc-
tions on how to report on-demand analgesia according
to the outcome assessment instruments and modalities.
Outcome measures
Outcome measures evaluated in each N-of-1 trial will be
the daily intensity of pain, the daily need of on-demand
analgesic medications, and the impact of pain on daily
activities measured over a week time (case 1: self-
assessment trials).
In the cases in which self-assessment is not feasible
(case 2: caregiver-based assessment trials) the daily fre-
quency with which the patient complains of pain mea-
sured by the patient’s caregiver will be adopted as the
outcome measure, since the measurement of the fre-
quency of pain complaints by someone other than the
patient is expected to be more feasible than the quantifi-
cation of pain intensity. The daily need of on-demand
analgesic medications and the impact of pain on daily
activities over a week will also be evaluated in case 2
trials.
For the purpose of deciding for the optimal treatment in
the patient, all the listed outcome measures will be valued.
For meta-analytical purposes, the daily intensity of pain
(case 1) or the daily frequency of pain symptoms (case 2)
will be the primary outcome measure; the daily need of
on-demand analgesic medications, and the impact of pain
on daily activities will be the secondary outcome measures.
Instruments, timing, and modalities of assessment
Case 1 (self-assessment)
Pain intensity will be assessed daily using an 11-point
(from 0 to 10) visual numeric scale [45]. To help with
the assessment, in the paper used for the assessment,
the numeric horizontal line will be accompanied with la-
bels and pictures (modified from the Faces Pain Scale
[46]) expressing the intensity of pain (Fig. 2). The patient
or caregiver will also be asked to report the daily use of
on-demand analgesic medications, specifying the type
and dosage of drug taken (Fig. 2). The impact of pain on
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patient daily activities will be evaluated at the baseline
and at the end of each week, using a short questionnaire
modified from the Back Pain Functional Scale [47]. This
is a self-report measure to evaluate the patient’s functional
status, proposed for use in both clinical and research
settings. It consists of 12 items (derived from existing
questionnaires and interviews with physical therapists),
investigating work, hobbies, home activities, bending or
stooping, dressing shoes or socks, lifting, sleeping, stand-
ing, walking, climbing stairs, sitting, and driving. It has
been validated [48] and extensively used [49–52], even
with older people [53]. The scale was selected among the
several available instruments for functional impairment
due to chronic pain because of its comprehensiveness
combined with a reasonable number of items. The ques-
tionnaire takes about 5 min to complete. Although it was
conceived as a scale for back pain evaluation, the study
authors also judged it as adequate to assess the functional
impact of any osteoarticular or neuropathic pain. Al-
though the scale has been used with older people, we
slightly modified the Back Pain Functional Scale to make
it more appropriate for geriatric patients. We reduced the
walking distance from 1 mile (1610 m) to 200 m and the
number of stairs from 20 to 10. In addition, we substituted
the original rating scale (over six points) with a Likert
five-point scale, in which 1 corresponds to ‘no difficulty to
perform activity’, 2 to ‘a little bit of difficulty’, 3 to ‘medium
difficulty’, 4 to ‘great difficulty’, and 5 to ‘impossibility to
perform the activity’. The modified Back Pain Functional
Scale is reported in Fig. 3. The total score is obtained as a
mean of the scores for all items. When required, the ques-
tionnaire will be tailored to the patient usual activity and
performance, thus removing those items that do not apply
(e.g. if the patient does not drive, the question referring to
driving will be removed). If at the enrollment visit the
patient appears to value the impairment of one daily activ-
ity that is not included in the questionnaire, a specific item
will be added.
At the baseline visit, the ability of the patient to com-
pile the questionnaire unaided after instructions will be
verified. If any limitation arises, the patient’s caregiver
will be engaged and trained to take responsibility for
completing the assessment.
Case 2 (caregiver-based assessment)
The participating caregiver and treating physician will
be asked to identify the pain symptoms and to meas-
ure the daily frequency with which the patient com-
plains of them using a five-point scale: 1 corresponds
to ‘never’, 2 to ‘once’, 3 to ‘sometimes’, 4 to ‘often’, and
5 to ‘continuously’.
The impact on daily living will be measured by identi-
fying those patient activities most affected by chronic
pain (e.g. walking, sleeping, transfers) and building a
personalized instrument through which the impact on
each activity will be measured using a five-point scale
similar to the one used for case 1 patients.
The use of on-demand analgesic medications will be
reported daily by the participating caregiver, specifying
the type of drug taken and its dosage.
Impact of N-of-1 trial on physician’s management plan
To assess the impact of the N-of-1 trial on the physician’s
management plan, we will preliminarily ask each physician
if he or she would treat the patient with um-PEA
independently of the N-of-1 trial; once the N-of-1
trial results become available, we will ask how the
physician intends to treat the patient. Management
plan options will include continuing or withdrawing
um-PEA. We will also investigate the level of the
Fig. 2 Pain assessment scale
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physician’s confidence in the management plan,
both before and after the N-of-1 trial, using a
seven-point scale. The physicians will be asked the
following [42]:
How comfortable do you feel now about your treat-
ment plan?
1. Totally comfortable; certain it is the right thing for
the patient.
2. Almost totally comfortable; very probably it is the
right thing for the patient.
3. Quite comfortable; it is probable that the treatment
plan is best for the patient.
Fig. 3 Questionnaire for functional status assessment
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4. Not totally comfortable; but treatment likely to be as
good as alternatives.
5. Mildly uncomfortable; some uncertainty whether
treatment plan is best for the patient.
6. Moderately uncomfortable; feeling that the
treatment plan might not be the best for the patient.
7. Extremely uncomfortable; uncertain about treatment
plan and, if wrong, patient may suffer.
Participant timeline
The study timeline is reported in Fig. 1.
At the enrollment visit, eligibility criteria will be
checked, informed consent will be obtained, and data re-
garding patient socio-demographics, pain characteristics,
comorbidities, and pharmacotherapy will be collected.
The clinical investigators will also evaluate the ability of
the patient and the caregiver to assess pain intensity,
and appropriate training for questionnaire fulfilment will
be performed.
After allocation, the study drug will be delivered to the
patient (case 1) or caregiver (case 2) and baseline pain
intensity and functional status will be recorded.
The patient or caregiver will be contacted by tele-
phone after the first week of treatment to investigate
possible issues concerning therapeutic adherence, ad-
verse effects, and questionnaire completion. A visit with
the patient and caregiver will be scheduled before the
beginning of each period, to deliver the study drug and
acquire the completed questionnaires, checking their
correct fulfilment. At the end of the last period, the last
questionnaires will be collected.
A final visit with the patient will be scheduled at the
end of the trial, once the study results are available. The
patient, the caregiver, the treating physician, and the
study investigators will discuss the study results.
Allocation and blinding
The sequence will be generated by the pharmacist using
the web site www.randomizer.org. Two sets of two
random numbers (numerals 1 [arbitrarily designated as
placebo] or 2 [designated as active]), with each number in
a set remaining unique, will be generated for each patient.
Pharmacists will be recording the allocation sequence and
will provide the study drug (either active drug or placebo,
indistinguishable) to the clinical investigators at the
beginning of each study period. Patients, participating
caregivers, treating physicians, and clinical investigators
(responsible for outcome assessment and data analysis)
will be blinded to the treatment sequence.
Unblinding will be permissible at any time that the
trial will be considered concluded. Reasons for which
the trial will be deemed concluded other than its com-
pletion will be: the patient withdraws consent; the pa-
tient or the treating physician is convinced that drug
effectiveness has been established or refuted before the
end of the designed trial; and safety concerns.
Sample size
For each N-of-1 trial, the sample size is represented by the
number of periods of treatment. The choice to design
each trial including two treatment pairs is not based on a
formal power calculation, considering that N-of-1 trials
with a practicable number of pairs can rarely reach the
conventional level of statistical power of 80–90 % [54].
The choice is a trade-off between the desire of a trial as
powerful as possible, and the practical need to limit its
duration, given the required length of each period and of
the washout between each treatment period. However,
considering the actual objective of each N-of-1 trial, two
treatment pairs seem a reasonable choice, given the start-
ing good level of confidence on the treatment effectiveness
that our geriatric team derived from the brief experience
with the product (based on conventional trials) we prelim-
inarily had in our practice.
A meta-analysis of the performed N-of-1 trials to esti-
mate an overall population treatment effectiveness and
evaluate the possible determinants of the effect heterogen-
eity between trials will be a proof-of-concept study. Given
the explorative nature of this secondary objective, the
number of N-of-1 trials that will be meta-analyzed is
not dictated by a specific sample size calculation. A
first meta-analysis will be performed on those com-
pleted N-of-1 trials initiated during the first 12 months
from the start of the first N-of-1 trial, as long as
there are at least three trials. A second meta-analysis
will be performed including all the N-of-1 trials initiated
within 24 months from the start of the first N-of-1 trial
(study duration).
The posterior probability that um-PEA is better than pla-
cebo for a certain patient (single trial) and for the popula-
tion (trial series) will be provided through a Bayesian
approach.
Statistical methods
According to the objectives of the study, we will first
analyze results within each N-of-1 trial and, secondarily,
we will combine results across them.
Analysis of individual N-of-1 trials
Results on daily pain intensity will be summarized, cal-
culating first the mean symptom score of each week in
each period, and then the mean score in each period.
The week and period mean scores will be paired with
the treatment administered in each period, in a cross-
tabulation and in a graph. A similar synthesis will be
used for the scores on the week impact on function. A
paired t test will be used for the statistical comparison of
period mean scores within treatment pairs.
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At first, the analyses will be performed assuming that
the washout periods were sufficient to overcome the
possible carryover effect of PEA. If a slow onset time or
a residual carryover effect are suspected from the qualita-
tive (‘at a glance’) evaluation of the week (mean) outcome
measures including those made during the washout pe-
riods, a sensitivity analysis will be conducted. In this sec-
ond analysis, a paired t test will be repeated after having
excluded from the calculation of the period mean scores
the measures made during the first week of each period.
If more than three measures of the daily pain intensity in
the same week are missing for at least one week, the period
mean score will be computed, weighting each week mean
score according to the inverse-variance method [55].
To make the final treatment decision as objective as
possible, the results of each N-of-1 trial will first be evalu-
ated by the physician and the patient or caregiver (when
feasible), keeping the nature of the two treatments covered
(i.e. naming the treatments simply A and B); then, the
code will be broken and the nature of treatments revealed.
Meta-analysis of N-of-1 trial series
A linear mixed effect model [56] will be performed, with
the week mean pain intensity score or the week impact-
on-function score as dependent variable and the patient
included as random effect (random intercept). The pri-
mary analyses will include treatment as the single ex-
planatory variable with fixed effect. Secondly, a random
coefficient for treatment (i.e. treatment effect varying be-
tween patients) will be tested. A random intercept for
pair, in a nested structure (outcome measures within pa-
tients, and patients within pairs) will also be tested. A
possible residual carryover effect (>2 weeks) will finally
be tested, including sequence, pair, treatment by se-
quence interaction, and treatment by pair interaction as
fixed-effects. The models will be also repeated excluding
the first week measures of each period.
Patient-level (or study-level) variables will also be
tested in the analyses as possible explanatory variables of
treatment effect heterogeneity.
In addition to the classic (frequentist) analysis, results
of the individual trials and their combination will be
approached using Bayesian hierarchical methods, as de-
scribed by Zucker et al. [57]. Non-informative priors will
initially be modeled. In addition, physician’s pre-trial con-
fidence in treatment effectiveness will be used to model
informative priors.
Evaluation of N-of-1 trials on PEA
To evaluate the usage and usefulness of the performed
N-of-1 trials, each trial will be classified according to:
! its completeness, defining as complete those trials
conducted to the term; as incomplete with clinical
decision those trials interrupted before the
completion of the planned treatment pairs because
the physician and patient or caregiver were at that
point convinced of the effectiveness or lack of
effectiveness of PEA (notwithstanding the blinding);
and as incomplete for other reasons those trials
interrupted before the completion of the planned
treatment pairs because of other reasons (patient
compliance, consent withdrawn, concurrent illness,
death, etc.);
! the achievement of statistically significant results,
setting P ≤ 0.1 as the criterion to define a statistically
significant mean effect difference between PEA and
placebo;
! the direction of results, i.e. a beneficial or harmful
effect of PEA compared with placebo when a
statistically significant mean effect difference is found.
Monitoring
Owing to the small amount of data to be managed and
to the absence of funding, a data monitoring committee
is not recruited. Data will be managed and monitored
directly by the study investigators. The correct use of
the study drug and instruments, and possible adverse ef-
fects will be monitored at each phone or in person con-
tact with the patient. Patients will be encouraged to
report any possible adverse effect or concern about the
study for the whole study duration through the provided
investigators’ phone contacts.
Data management
Data will be stored in an electronic database, protected
by password.
Discussion
Um-PEA might represent an effective and safe option
for older patients with chronic pain. We opted to inves-
tigate this hypothesis at the individual level, in our rou-
tine practice, applying the N-of-1 approach to a geriatric
population. Research and clinical practice become intim-
ately intertwined on the ground of geriatric N-of-1 trials.
Indeed, while they borrow typical research instruments
(e.g. randomization, placebo) to achieve their ultimate
clinical objective, i.e. to determine the best therapeutic
choice for patients, reliably and empirically, they also
meet the aims of innovative and timely research. They
bring principles of evidence-based medicine into the
care of older patients scarcely represented in conventional
randomized controlled trials. Moreover, N-of-1 trials
promote and exploit a patient-centered research that
goes beyond the need of generalizability and even beyond
the limits of the comparative effectiveness research. In par-
ticular, they embody the spirit of patient-centered outcomes
research necessary to prioritize medicaments and improve
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appropriate prescribing in older patients with multimorbid-
ity and polypharmacy [58]. Patient-centered outcomes re-
search is indeed possible even with older patients who,
contrary to expectations, have been shown to take into
account competing outcomes when deciding on thera-
peutic alternatives, and to value the effects of treatments
on cognitive, physical, and emotional functions [59].
We also expect that putting the patient at the center
of our practice and research, modifying the trial design
according to patient expectations, needs, and difficulties,
might help to mitigate those well-known barriers con-
cerning participant enrollment and adherence encoun-
tered in the conduction of trials involving older persons.
Learning how to listen to the patient’s needs, even when
not traditionally expressed, makes patient-centered prac-
tice and research possible even with cognitively impaired
people. In particular, this series of N-of-1 trials on PEA
will help to enhance our capabilities to interpret, meas-
ure, and treat pain in its alternative expressions.
The meta-analysis of the N-of-1 trials on PEA we con-
duct will provide aggregate information on the product
that can be used to inform treatment decisions for other
patients not participating in the trials.
Finally, the project, in its entirety, will represent a way
of filling the gap between science and practice, facilitat-
ing the involvement of patients and clinicians in the pro-
duction of evidence, and promoting the creation of ‘a
real clinical learning community’ [60].
Trial status
At the time of manuscript submission, four patients have
been enrolled and randomization has begun.
Additional file
Additional file 1: SPIRIT 2013 checklist. (DOC 120 kb)
Additional file 2: CENT 2015 checklist*; CONSORT 2010 checklist items
with modifications or additions for individual or series of N-of-1 trials;
empty items in the CENT 2015 column indicate no modification from the
CONSORT 2010 item. (DOCX 97.2 kb)
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